General Information
Boehringer Ingelheim DM 2 1245.31 Ext
A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (incl. 24 weeks of preceding trial) as monotherapy or with different back-ground therapies in patients with type 2 diabetes mellitus previously completing trial 1245.19, 1245.20 or 1245.23.
| Protocol | |
|---|---|
| Identifier | 1245.31 Site Number 10154 |
| UID | 91bdcffd-6d08-4eea-a6df-235ac2473b2b |
| Status | Done - Archived |
| Phase | 3 |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 2011 |
| NCT Number | - |
| Created | 2011-04-06 16:14 |
| Last Updated | 2011-04-06 16:14 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2011-09-29 | No |
| PI Meeting Start | 2012-04-29 | No |
| PI Meeting End | 2012-04-29 | No |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2013-09-10 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | - | No | |
| Coordinator | Mata, Nelly | NMata | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Boehringer Ingelheim Pharmaceuticals, Inc. |
|---|---|
| Division | Boehringer Ingelheim Pharmaceuticals |
| Team | Boehringer Ingelheim Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | Pro00006230 |
|---|---|
| CRO | |
| CRO Ref | CRA: Dale Jones - Tel 310-938-0125 |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
